ALGS · Aligos Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“our recurring losses from operations and negative cash flows have raised substantial doubt regarding our ability to continue as a going concern”View the 10-Q filed May 7, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-25 | Chavez Margarita |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
5,860 |
| 2026-06-25 | Hirth Peter |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
5,860 |
| 2026-06-25 | Nuechterlein Carole |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
5,860 |
| 2026-06-25 | Martell Bridget A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
5,860 |
| 2026-06-25 | Preston Heather |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
5,860 |
| 2026-06-25 | Scopa James Paul |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
5,860 |
| 2026-03-09 | Calhoun Lesley Ann |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
37,485 |
| 2026-03-09 | BLATT LAWRENCE |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
105,840 |
| 2026-03-09 | Aneja Nikhil |
Principal Accounting Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
9,450 |
| 2026-03-09 | Symons Julian A. |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
23,310 |
| 2025-07-16 | Calhoun Lesley Ann |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 16, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
40,185 |
| 2025-07-16 | Symons Julian A. |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 16, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
16,000 |
| 2025-07-16 | BLATT LAWRENCE |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 16, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
179,800 |
| 2025-06-25 | Scopa James Paul |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
5,860 |
| 2025-06-25 | Nuechterlein Carole |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
5,860 |
| 2025-06-25 | Martell Bridget A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
5,860 |
| 2025-06-25 | Preston Heather |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
5,860 |
| 2025-06-25 | Hirth Peter |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
5,860 |
| 2025-06-25 | Chavez Margarita |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
5,860 |
| 2025-02-28 | Calhoun Lesley Ann |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 28, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
47,271 |
| 2025-02-28 | BLATT LAWRENCE |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 28, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
140,103 |
| 2025-02-28 | Symons Julian A. |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 28, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
21,693 |
| 2024-10-08 | Achneck Hardean |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Twenty Five Percent (25%) of the shares subject to the option will vest on September 23, 2025 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
75,000 |
| 2024-09-23 | Achneck Hardean |
Chief Medical Officer |
Other↑
|
No Securities Owned
|
0 |
| 2024-09-04 | Calhoun Lesley Ann |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from September 4, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
10,880 |
| 2024-09-04 | BLATT LAWRENCE |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from September 4, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
33,920 |
| 2024-09-04 | Symons Julian A. |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from September 4, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
10,880 |
| 2024-08-07 | Chavez Margarita |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2024-08-07 | Preston Heather |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/36th of the total number of shares vest in thirty-six (36) successive and equal monthly installments measured from August 7, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. |
Stock Option (Right to Buy)
|
120,000 |
| 2024-08-07 | Preston Heather |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2024-08-07 | Chavez Margarita |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/36th of the total number of shares vest in thirty-six (36) successive and equal monthly installments measured from August 7, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. |
Stock Option (Right to Buy)
|
120,000 |
| 2024-06-27 | Scopa James Paul |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2025 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
60,000 |
| 2024-06-27 | Martell Bridget A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2025 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
60,000 |
| 2024-06-27 | Hirth Peter |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2025 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
60,000 |
| 2024-06-27 | Nuechterlein Carole |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2025 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Stock Option (Right to Buy)
|
60,000 |
| 2024-03-01 | Symons Julian A. |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
72,000 |
| 2024-03-01 | BLATT LAWRENCE |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
965,435 |
| 2024-03-01 | McClure Matthew W. |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
72,000 |
| 2024-03-01 | Calhoun Lesley Ann |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Stock Option (Right to Buy)
|
308,940 |
| 2024-02-28 | BLATT LAWRENCE |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 80,850 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 57,749 shares, having an exercise price of $0.96 per share. The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. |
Stock Option (Right to Buy)
|
57,749 |
| 2024-02-28 | Scopa James Paul |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's shares granted to the reporting person on April 26, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 8,823 shares, having an exercise price of $0.96 per share. The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. |
Stock Option (Right to Buy)
|
8,823 |
| 2024-02-28 | Nuechterlein Carole |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share. The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. |
Stock Option (Right to Buy)
|
4,411 |
| 2024-02-28 | Symons Julian A. |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share. The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date. |
Stock Option (Right to Buy)
|
74,998 |
| 2024-02-28 | BLATT LAWRENCE |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 450,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 132,352 shares, having an exercise price of $0.96 per share. The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. |
Stock Option (Right to Buy)
|
132,352 |
| 2024-02-28 | McClure Matthew W. |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 92,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 65,713 shares, having an exercise price of $0.96 per share. The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date. |
Stock Option (Right to Buy)
|
65,713 |
| 2024-02-28 | Calhoun Lesley Ann |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share. The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date. |
Stock Option (Right to Buy)
|
74,998 |
| 2024-02-28 | Hirth Peter |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share. The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. |
Stock Option (Right to Buy)
|
4,411 |
| 2024-02-28 | Nielsen Jack |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share. The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. |
Stock Option (Right to Buy)
|
4,411 |
| 2024-02-28 | BLATT LAWRENCE |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 323,400 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 230,999 shares, having an exercise price of $0.96 per share. The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date. |
Stock Option (Right to Buy)
|
230,999 |
| 2024-02-28 | McClure Matthew W. |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 23,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 16,428 shares, having an exercise price of $0.96 per share. The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. |
Stock Option (Right to Buy)
|
16,428 |